Dexlansoprazole injection - Jiangsu Aosaikang Pharmaceutical

Drug Profile

Dexlansoprazole injection - Jiangsu Aosaikang Pharmaceutical

Latest Information Update: 21 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Jiangsu Aosaikang Pharmaceutical
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Pyridines; Small molecules; Sulfoxides
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Erosive oesophagitis; Gastro-oesophageal reflux

Most Recent Events

  • 14 Apr 2017 Zhejiang University and Jiangsu Aosaikang Pharmaceutical initiate enrolment in a phase I trial in Healthy volunteers in China (NCT03120273)
  • 09 Mar 2017 Jiangsu Aosaikang Pharmaceutical completes a phase I trial in Gastro-oesophageal reflux and Erosive oesophagitis (In volunteers) in China (NCT03011125)
  • 01 Jan 2017 Phase-I clinical trials in Erosive oesophagitis (In volunteers) in China (IV) (NCT03011125)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top